State Street’s Lipocine LPCN Stock Holding History

State Street’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$179K	Buy	22,407 +3,781	+20%	+$32.9K	﹤0.01%	3912
2025 Q4	$150K	Hold	18,626	–	–	﹤0.01%	3966
2025 Q3	$53.3K	Hold	18,626	–	–	﹤0.01%	4147
2025 Q2	$58.9K	Hold	18,626	–	–	﹤0.01%	4072
2025 Q1	$59.2K	Hold	18,626	–	–	﹤0.01%	4068
2024 Q4	$90.9K	Hold	18,626	–	–	﹤0.01%	4008
2024 Q3	$83.6K	Hold	18,626	–	–	﹤0.01%	4010
2024 Q2	$153K	Hold	18,626	–	–	﹤0.01%	3889
2024 Q1	$96.9K	Hold	18,626	–	–	﹤0.01%	4035
2023 Q4	$51.4K	Hold	18,626	–	–	﹤0.01%	4193
2023 Q3	$54.8K	Hold	18,626	–	–	﹤0.01%	4262
2023 Q2	$93.1K	Buy	18,626 +1	+0%	+$5	﹤0.01%	4259
2023 Q1	$101K	Hold	18,625	–	–	﹤0.01%	4325
2022 Q4	$122K	Hold	18,625	–	–	﹤0.01%	4308
2022 Q3	$142K	Hold	18,625	–	–	﹤0.01%	4290
2022 Q2	$254K	Sell	18,625 -634	-3%	-$9.88K	﹤0.01%	4099
2022 Q1	$449K	Buy	19,259 +1,340	+7%	+$28K	﹤0.01%	4095
2021 Q4	$302K	Hold	17,919	–	–	﹤0.01%	4182
2021 Q3	$332K	Hold	17,919	–	–	﹤0.01%	4137
2021 Q2	$426K	Buy	17,919 +17,190	+2,358%	+$404K	﹤0.01%	3921
2021 Q1	$19K	Hold	729	–	–	﹤0.01%	3965
2020 Q4	$17K	Hold	729	–	–	﹤0.01%	3872
2020 Q3	$17K	Hold	729	–	–	﹤0.01%	3803
2020 Q2	$16K	Hold	729	–	–	﹤0.01%	3778
2020 Q1	$6K	Hold	729	–	–	﹤0.01%	3739
2019 Q4	$5K	Hold	729	–	–	﹤0.01%	3801
2019 Q3	$35K	Hold	729	–	–	﹤0.01%	3738
2019 Q2	$24K	Hold	729	–	–	﹤0.01%	3767
2019 Q1	$29K	Hold	729	–	–	﹤0.01%	3697
2018 Q4	$16K	Hold	729	–	–	﹤0.01%	3721
2018 Q3	$18K	Sell	729 -53	-7%	-$1.3K	﹤0.01%	3740
2018 Q2	$18K	Sell	782 -136	-15%	-$3.24K	﹤0.01%	3736
2018 Q1	$24K	Hold	918	–	–	﹤0.01%	3708
2017 Q4	$53K	Hold	918	–	–	﹤0.01%	3639
2017 Q3	$63K	Hold	918	–	–	﹤0.01%	3652
2017 Q2	$63K	Sell	918 -13,167	-93%	-$859K	﹤0.01%	3575
2017 Q1	$935K	Buy	14,085 +199	+1%	+$12.9K	﹤0.01%	3286
2016 Q4	$867K	Buy	13,886 +74	+0.5%	+$4.68K	﹤0.01%	3306
2016 Q3	$1.05M	Buy	13,812 +2,007	+17%	+$124K	﹤0.01%	3181
2016 Q2	$609K	Buy	11,805 +11,023	+1,410%	+$1.71M	﹤0.01%	3361
2016 Q1	$135K	Hold	782	–	–	﹤0.01%	3523
2015 Q4	$172K	Buy	782 +11	+1%	+$2.31K	﹤0.01%	3498
2015 Q3	$156K	Buy	771 +30	+4%	+$6.94K	﹤0.01%	3493
2015 Q2	$108K	Buy	+741	New	+$92K	﹤0.01%	3533

Other funds holding LPCN

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

SFCM

Seven Fleet Capital Management Mountain View, California $318M AUM

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

State Street's LPCN Position: Q1 2026 in Review

State Street increased its Lipocine (LPCN) stake by 20% in Q1 2026, buying an estimated $32.9K and bringing the position to 22,407 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #3912.

State Street first reported a position in LPCN in Q2 2015 and has held it in 44 quarters since. The position peaked at $1.05M in Q3 2016. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

State Street held 22,407 shares of Lipocine worth $179K as of Q1 2026.
State Street bought 3,781 Lipocine shares in Q1 2026, an estimated $32.9K.
Lipocine made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3912 holding.
State Street first reported a position in Lipocine in Q2 2015 and has held it in 44 quarters since.
State Street's Lipocine position peaked at $1.05M in Q3 2016.
47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.